CPAP promotes angiogenesis and metastasis by enhancing STAT3 activity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CPAP promotes angiogenesis and metastasis by enhancing STAT3 activity
Authors
Keywords
-
Journal
CELL DEATH AND DIFFERENTIATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-11
DOI
10.1038/s41418-019-0413-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of mTOR Signaling in Tumor Microenvironment: An Overview
- (2018) Fabiana Conciatori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tip110/SART3 regulates IL-8 expression and predicts the clinical outcomes in melanoma
- (2018) Khalid Amine Timani et al. Molecular Cancer
- An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma
- (2017) Jean-Luc Raoul et al. EXPERT OPINION ON PHARMACOTHERAPY
- Global trends and predictions in hepatocellular carcinoma mortality
- (2017) Paola Bertuccio et al. JOURNAL OF HEPATOLOGY
- Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma
- (2017) Ai-Qing Lu et al. ONCOLOGY REPORTS
- Translational upregulation of Aurora-A by hnRNP Q1 contributes to cell proliferation and tumorigenesis in colorectal cancer
- (2017) Chien-Hsien Lai et al. Cell Death & Disease
- Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis
- (2016) Yangkun Luo et al. Cancer Cell International
- miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression
- (2016) Junya Azumi et al. CANCER SCIENCE
- High platelet counts increase metastatic risk in huge hepatocellular carcinoma undergoing transarterial chemoembolization
- (2016) Tong-Chun Xue et al. HEPATOLOGY RESEARCH
- Interleukin-8 and Interleukin-17 for Cancer
- (2014) Paul Zarogoulidis et al. CANCER INVESTIGATION
- Chemokines in Cancer
- (2014) M. T. Chow et al. Cancer Immunology Research
- SUMOylated CPAP is required for IKK-mediated NF-κB activation and enhances HBx-induced NF-κB signaling in HCC
- (2013) Shu-Ting Yang et al. JOURNAL OF HEPATOLOGY
- Activation of the NF-κB Pathway by the STAT3 Inhibitor JSI-124 in Human Glioblastoma Cells
- (2013) Braden C. McFarland et al. MOLECULAR CANCER RESEARCH
- NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer
- (2013) Yihui Fan et al. Protein & Cell
- The liver-specific tumor suppressor STAT5 controls expression of the reactive oxygen species-generating enzyme NOX4 and the proapoptotic proteins PUMA and BIM in mice
- (2012) Ji Hoon Yu et al. HEPATOLOGY
- STAT3 activation in monocytes accelerates liver cancer progression
- (2011) Wen-Yong Wu et al. BMC CANCER
- NF-κB and STAT3 – key players in liver inflammation and cancer
- (2010) Guobin He et al. CELL RESEARCH
- Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells
- (2010) Yan Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Autotaxin expression and its connection with the TNF-alpha-NF-κB axis in human hepatocellular carcinoma
- (2010) Jian-Min Wu et al. Molecular Cancer
- Angiogenesis: From Chronic Liver Inflammation to Hepatocellular Carcinoma
- (2010) Paloma Sanz-Cameno et al. Journal of Oncology
- Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation
- (2009) Atsushi Hosui et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CPAP is a cell-cycle regulated protein that controls centriole length
- (2009) Chieh-Ju C. Tang et al. NATURE CELL BIOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More